NCT07046221 2025-07-20Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or SurgeryFujian Cancer HospitalPhase 2 Not yet recruiting60 enrolled
NCT06066216 2024-01-23Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial CancerFujian Cancer HospitalPhase 2 Not yet recruiting45 enrolled